Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: A systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis

Psychiatry Research

Volumn 228, Issue 1, 2015, Pages 121-127

  Chen, Xichuang ^a   Hong, Yuan ^b   Zheng, Panpan ^c  

^a Wuxi 9th People s Hospital Affiliated to Suzhou Medical College of Soochow University   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NINGBO NO 6 HOSPITAL   (China)

Author keywords

Chronic schizophrenia; EGb 761; Ginkgo biloba; Meta analysis; Review

Indexed keywords

GINKGO BILOBA EXTRACT; NEUROLEPTIC AGENT; PLACEBO; PLANT EXTRACT;

ADJUVANT THERAPY; ARTICLE; BEHAVIOR DISORDER; CHINA; CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS; SCHIZOPHRENIA; SIDE EFFECT; SIDE EFFECT ASSESSMENT; SYSTEMATIC REVIEW; TACHYCARDIA; THIRST; TREATMENT EMERGENT SYMPTOM SCALE; DOUBLE BLIND PROCEDURE; GINKGO BILOBA; MULTIMODALITY CANCER THERAPY; PHYTOTHERAPY;

ANTIPSYCHOTIC AGENTS; CHINA; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; GINKGO BILOBA; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84930044754     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.04.026     Document Type: Article

References (49)

1. Abdalla D.S., Monteiro H.P., Oliveira J.A., Bechara E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. Clinical Chemistry 1986, 32(5):805-807.
2. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. The American Journal of Psychiatry 1999, 156(11):1686-1696.
3. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Archives of General Psychiatry 1982, 39(7):789-794.
4. Andrieu S., Ousset P.J., Coley N., Ouzid M., Mathiex-Fortunet H., Vellas B., GuidAge study GROUP GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Current Alzheimer Research 2008, 5(4):406-415.
5. Brondino N., De Silvestri A., Re S., Lanati N., Thiemann P., Verna A., Emanuele E., Politi P. A systematic review and meta-analysis of Ginkgo biloba in neuropsychiatric disorders: from ancient tradition to modern-day medicine. Evidence Based Complementary and Alternative Medicine 2013, 2013:915691.
6. Carpenter W.T., Koenig J.I. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008, 33(9):2061-2079.
7. Diamond B.J., Shiflett S.C., Feiwel N., Matheis R.J., Noskin O., Richards J.A., Schoenberger N.E. Ginkgo biloba extract: mechanisms and clinical indications. Archives of Physical Medicine and Rehabilitation 2000, 81(5):668-678.
8. Doruk A., Uzun O., Ozşahin A. A placebo-controlled study of extract of Ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. International Clinical Psychopharmacology 2008, 23(4):223-227.
9. Ettinger U., Meyhöfer I., Steffens M., Wagner M., Koutsouleris N. Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia. Frontiers in Psychiatry 2014, 5:18.
10. Flatow J., Buckley P., Miller B.J. Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry 2013, 74(6):400-409.
11. Higgins, J.P.T., Green, S., 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available at:. http://www.cochrane-handbook.org.
12. Jia J., Zhu F., Ma X., Cao Z., Li Y., Chen Y.Z. Mechanisms of drug combinations: interaction and network perspectives. Nature Reviews Drug Discovery 2009, 8(2):111-128.
13. Kleijnen J., Knipschild P. Ginkgo biloba for cerebral insufficiency. British Journal of Clinical Pharmacology 1992, 34(4):352-358.
14. Kleijnen J., Knipschild P. Ginkgo biloba. Lancet 1992, 340(8828):1136-1139.
15. Knable M.B. Extract of Ginkgo biloba added to haloperidol was effective for positive symptoms in refractory schizophrenia. Evidence Based Mental Health 2002, 5(3):90.
16. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function 2002, 20(2):171-175.
17. Le Bars P.L., Velasco F.M., Ferguson J.M., Dessain E.C., Kieser M., Hoerr R. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology 2002, 45(1):19-26.
18. Lehár J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., Rickles R.J., Short G.F., Staunton J.E., Jin X., Lee M.S., Zimmermann G.R., Borisy A.A. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology 2009, 27(7):659-666.
19. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry 2003, 160(2):290-296.
20. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Archives of General Psychiatry 1991, 48(12):1097-1106.
21. Luo H.C., Shen Y.C., Meng F.Q., Wang H.H., Yu J., Yi J.L., Liu G.Z., Zhong H.W., Zhang B., Lu L.L., Yang F.S., Zhang S.Q., Ma Q.M., Zhang Y.H., Zhu L.C., Zhu M.L., Zhu S.M., Chen Z. Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia-a double blind study (in Chinese). Chinese Journal of Integrated Traditional and Western Medicine 1997, 17(3):139-142.
22. Maclennan K.M., Darlington C.L., Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Progress in Neurobiology 2002, 67(3):235-257.
23. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biological Psychiatry 1998, 43(9):674-679.
24. Mahadik S.P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Research 1996, 19(1):1-17.
25. Mahadik S.P., Scheffer R.E. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996, 55(1-2):45-54.
26. Marcocci L., Packer L., Droy-Lefaix M.T., Sekaki A., Gardès-Albert M. Antioxidant action of Ginkgo biloba extract EGb 761. Methods in Enzymology 1994, 234:462-475.
27. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008, 30(1):67-76.
28. McKenna D.J., Jones K., Hughes K. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Alternative Therapies in Health and Medicine 2001, 7(5):70-86. 88-90.
29. Meng F.Q., Cui Y.H., Wang S.H., Yang X.D., Liu J.C., Tan C.X., Luo H.C. A double-blind placebo controlled study of EGb 761 in the treatment of chronic schizophrenia (in Chinese). Journal of Clinical Psychiatry 1996, 6(6):339-341.
30. Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 2010, 8(5):336-341.
31. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neuroscience Letters 2010, 479(3):317-320.
32. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biological Psychiatry 1991, 30(4):409-412.
33. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996, 55(1-2):33-43.
34. Schultz S.H., North S.W., Shields C.G. Schizophrenia: a review. American Family Physician 2007, 75(12):1821-1829.
35. Singh V., Singh S.P., Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. International Journal of Neuropsychopharmacology 2010, 13(2):257-271.
36. Smith J.V., Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. Journal of Alzheimer's Disease 2003, 5(4):287-300.
37. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 2013, 46:200-206.
38. Yang F.S., Xu J.Q., Fang R.L., Wang C.H., Wei P. Double blind controlled study of the effect of shuxuening combined with antipsychotics in the treatment of chronic schizophrenia (in Chinese). Sichuan Mental Health 1998, 11(3):169-177.
39. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Research 2000, 97(2-3):137-151.
40. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15(4):287-310.
41. Yi J.L., Ye S.X., Wu X.L., Xie Q., Quan S.H., Zhang X.Z., Xu C.S., Zhao Q., Li C.Y., Yin Y.Y., Luo H.C., Zhao X.Y. A double-blind contrast study of Ginkgo biloba EGb 761 for the treatment of chronic schizophrenia (in Chinese). Medical Journal of Chinese Civil Administration 1996, 8(5):279-281.
42. Yu J., Li S.Z., Zhao A.Q., Shen Z.M., Li F.H., Xue Z.G., Wang H.H., Li S.Q., Zhang S.Q. A randomized controlled study of shuxuening combined with antipsychotics in the treatment of chronic schizophrenia (in Chinese). Medical Journal of Chinese Civil Administration 1996, 8(4):219-221.
43. Zhang S.Q., Qiu H.M., Liu X.C., Guo C.Q., Zhang C.H., Xu C.X., Xu C.M., Zhang T.L., Wu X.W., Hao W.D., Li X.W., Ren Y.P. A double-blind contrast study of shuxuening for the treatment of residual schizophrenia (in Chinese). Shangdong Archives of Psychiatry 1997, 10(1):36-39.
44. Zhang W.F., Tan Y.L., Zhang X.Y., Chan R.C., Wu H.R., Zhou D.F. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry 2011, 72(5):615-621.
45. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81(2-3):291-300.
46. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology 2006, 188(1):12-17.
47. Zhang X.Y., Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. Journal of Clinical Psychopharmacology 2001, 21(1):85-88.
48. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. The Journal of Clinical Psychiatry 2001, 62(11):878-883.
49. Zhong H.W., Luo H.C., Jia Y.K., Zhao X.Y. A double-blind contrast study of shuxuening (extract of Ginkgo biloba) for the treatment of type II schizophrenia (in Chinese). Chinese Journal of Nervous and Mental Diseases 1996, 22(2):117-118.